Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world

• Main Authors: V. D. Zakiev, A. D. Gvozdeva, T. V. Martynyuk
• Format: Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 2020-03-01
• Series: Терапевтический архив
• Subjects: clinical and economic analysis; burden of disease; pulmonary hypertension; pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension
• Online Access: https://ter-arkhiv.ru/0040-3660/article/viewFile/33925/pdf

Pulmonary hypertension (PH) is a progressive disease which is characterized with the increase of pulmonary artery pressure and pulmonary vascular resistance. Such condition leads to right ventricular heart failure and premature death of patients. Pulmonary arterial hypertension (PAH) has the status of an orphan disease. However in Russia only idiopathic PH is included in the list of 24 life-threatening and chronic progressive rare diseases, while other forms of PH are not in it. Inclusion in this list guarantees drug provision for patients at the expense of the regional budget, while patients with other forms of PH can rely on free medication only if they have a disability. The lack of criteria for revising this list as well as the imperfection of legal regulation in the field of drug support for orphan diseases leads to high disability, a significant decrease in the duration and quality of life of patients with PH. As part of a multicriteria approach, a clinical and economic analysis of the disease burden can be one of the tools for policy development and decision-making on the distribution of funding in the healthcare. The article provides a review of the economic burden of various forms of PH in the world.